Both in the collection of our data and in our literature review, we have used the following definitions of complications, partly built on Pakarinen et al. and Ellenbogen et al. The definitions are aligned to make the results more comparable to other publications.
In that sense, the purpose of the paper is to provide a description of the PSS-cost nature, and construct a Cost-Engineering method aligned to such definition.
From all the above-mentioned definitions of 'global health', the character of global-as-supraterritorial is most closely aligned to the above definition of the agent described by Dodgson and colleagues, which makes an issue a 'global health issue' [ 15].
We used the software MODELLER-9v4 (16) to construct a homology model of profalcipain-2 (Fig. 5a), which aligned to mature falcipain-2, procathepsin L, procathepsin K, and procaricain at sequence identities of 100% (by definition, aligned with the sequence of the mature domain only), 30.6%, 30.9%, and 32.1% respectively (14, 20 24).
11 13 The ESPART trial is an ongoing phase III, multicentre RCT that has been designed to compare the efficacy and safety of controlled ovarian stimulation with a fixed-dose combination of r-hFSH plus r-hLH in a 2 1 ratio against r-hFSH monotherapy for multifollicular development in women with a POR, as per a definition aligned with the ESHRE Bologna criteria.
Therefore, the objective of the ESPART trial is to explore the possible superiority of a fixed-dose combination of r-hFSH plus r-hLH over r-hFSH monotherapy in patients with POR, as per a definition aligned with the European Society of Human Reproduction and Embryology (ESHRE) Bologna criteria.
The primary objective of the study is to demonstrate the superiority of a fixed-dose combination of r-hFSH plus r-hLH in a 2 1 ratio over r-hFSH monotherapy in patients with a POR, as per a definition aligned with the ESHRE Bologna criteria.
The objective of the ESPART trial is to explore the possible superiority of a fixed-dose combination of r-hFSH plus r-hLH in a 2 1 ratio over r-hFSH monotherapy in patients with a POR, as per a definition aligned with the European Society of Human Reproduction and Embryology (ESHRE) Bologna criteria.
The ESPART trial, which is being conducted at more than 90 sites in 18 European countries, has been specifically designed to compare the efficacy and safety of controlled ovarian stimulation with a fixed-dose combination of r-hFSH plus r-hLH in a 2 1 ratio with r-hFSH monotherapy for multifollicular development in poor ovarian responders, as per a definition aligned with the Bologna criteria.
